Efficacy and Safety of IQP-VV-102 in Weight Management
Phase 3
Completed
- Conditions
- OverweightObesity
- Interventions
- Dietary Supplement: IQP-VV-102Other: Placebo
- Registration Number
- NCT01681069
- Lead Sponsor
- InQpharm Group
- Brief Summary
Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- Age 18 to 60 years
- 25 kg/m2 ≤ BMI ≤ 35 kg/m2
- Written informed consent
Exclusion Criteria
- Known sensitivity to sources of the active ingredients and excipients
- Pregnancy or nursing
- Inability to comply with study requirements, e.g. due to language difficulties
- Participation in another study during the last 30 days of the screening visit
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description IQP-VV-102 IQP-VV-102 2 tablets twice a day Placebo Placebo 2 tablets twice a day
- Primary Outcome Measures
Name Time Method Change in Body Weight at End of Study Compared to Baseline 12 weeks Change in body weight at the end of study compared to baseline
- Secondary Outcome Measures
Name Time Method Change in Waist Circumference (in cm) at End of Study From Baseline 12 weeks Difference in waist circumference (in cm) at end of study from baseline
Change in Mean Body Fat at End of Study From Baseline 12 weeks Measured in kg using calibrated weighing scales
Trial Locations
- Locations (1)
Barbara Grube
🇩🇪Berlin, Germany